Pharmaceuticals

• • Pipeline Code
  • Estimated Initial indication
  • Originator
• Pre-
  clinical
• Clinical Study
  Phase 1
• Clinical Study
  Phase 2
• Clinical Study
  Phase 3
• NDA
• Approval
• Launch
• Partner

• SP-01

  Chemotherapy Induced Nausea and Vomiting

  ProStrakan(Kyowa Kirin)
  overview
• China (Solasia)
  Taiwan, Singapore etc. (Kyowa Hakko Kirin : Sublicensee)
  US, EU, over 10 countries（Sancuso^®by other companies)

• Kyowa Hakko Kirin：

  Hong Kong, Macau, Taiwan, Malaysia, Singapore

  Lee’s Pharma：

  China Mainland w/o Beijing, Shanghai, Guangzhou, Hong Kong and Macau

• SP-02

  Peripheral T-Cell Lymphoma

  ZIOPHARM Oncology, Inc
  overview
• Japan, Korea, Taiwan, HK　（Phase II, pivotal Study）
  China　（Phase II/III, pivotal study preparation）
  US　(Phase IIA, completion）
  EU　(Pre-clinical, completion)

• Meiji Seika Pharma：

  Japan

  HB Human BioScience SAS：

  Latin America

• SP-04

  Chemotherapy Induced Peripheral Neuropathy (CIPN)

  PledPharma AB
  overview
• Japan, South Korea, Taiwan, HK (Phase III)
  China
  US and EU (Phase III by PledPharma)

Medical Device

• • Pipeline Code
  • Estimated Initial indication
  • Originator
• Pre-clinical
• Clinical Study
• NMDA
• Approval
• Launch
• Partner

• SP-03

  Pain associated oral mucositis

  Camurus AB
  overview
• Japan
  China
  Korea
  US, EU, over 9 countries （episil^® by other companies）

• Meiji Seika Pharma：

  Japan

  Lee’s Pharma：

  China Mainland w/o Beijing, Shanghai, Guangzhou and Taiwan